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The prognosis for adult T cell leukemia/lymphoma (ATL) is very poor, and only allogeneic hematopoietic stem
cell transplantation (allo-SCT) has been considered to be a curative treatment for ATL. In this study, we
retrospectively analyzed data for patients who had received allo-SCT for ATL in Hokkaido, the northernmost
island of Japan, to determine prognostic factors. Fifty-six patients with a median age of 57 years received allo-
SCT. Twenty-eight (50.0%) patients had acute type and 22 (46.4%) had lymphoma type. Twenty-three (41.1%)
patients received allo-SCT in complete remission (CR), whereas the others were in non-CR. Seventeen (30.4%)
patients received myeloablative conditioning and the others received reduced-intensity conditioning. With a
median follow-up period of 48 months (range, 17 to 134 months), 1-year overall survival (OS) and 5-year OS
rates were 55.4% and 46.1%, respectively. The survival curve reached a plateau at 22 months after stem cell
transplantation (SCT). Male sex, high level of serum soluble interleukin-2 receptor (sIL-2R) at SCT, and non-CR
at SCT were determined to be signiﬁcant risk factors for OS. A high level of sIL-2R at SCT was a risk factor for
poor OS in patients with non-CR at SCT by univariate analysis (P ¼ .02), and it remained signiﬁcant after
adjustment by sex (hazard ratio, 2.73 [95% conﬁdence interval, 1.07 to 7.90]). A high level of sIL-2R at SCT was
also determined to be a risk factor for disease progression (P ¼ .02). This region-wide study showed
encouraging results for survival after allo-SCT for ATL and demonstrated for the ﬁrst time that a high level of
sIL-2R at SCT predicts worse SCT outcome.
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Adult T cell leukemia/lymphoma (ATL) is a peripheral T
cell lymphoma caused by human T cell lymphotropic virus
type 1 (HTLV-1), and the prognoses of aggressive subtypes
(acute type and lymphoma type) of ATL are very poor [1].
Although only allogeneic hematopoietic stem cell trans-
plantation (allo-SCT) has been considered to be a curative
treatment for aggressive subtypes of ATL [2], less than 40% of
patients who have received allo-SCT have been cured [3-5].
We previously reported excellent outcomes for ATL patients
who received allo-SCT from 2 institutions in Hokkaido, the
northernmost island of Japan [6], and overall survival (OS)
rate in that study was 73.3% at 3 years after allo-SCT. We,
therefore, conducted a region-wide retrospective study indgments on page 805.
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Collection of Data
Clinical data for 56 patients who received allo-SCT for ATL between
January 2000 and March 2012 were collected from all stem cell trans-
plantation (SCT) centers in Hokkaido, Japan. The patients included all pa-
tients with ATL who received allo-SCT in this area. This study was conducted
with the approval of the institutional review board of Hokkaido University
Hospital. Conditioning regimens and other procedures of SCT were per-
formed according to the decision of the clinicians at each center.Deﬁnitions
Shimoyama’s classiﬁcation was used for the deﬁnition of ATL subtypes
[7]. Neutrophil engraftment and platelet engraftment were deﬁned as the
ﬁrst of 3 days with absolute neutrophil count > .5  109/L and the ﬁrst of 7
days with an untransfused platelet count > 50  109/L, respectively. The
hematopoietic cell transplant comorbidity index was scored by the criteria
previously described [8]. Acute graft-versus-host disease (AGVHD) and
chronic GVHD (CGVHD) were graded by standard criteria [9,10].
Transplantation-relatedmortality (TRM)was deﬁned as anydeath other than
death from ATL. OS was calculated from the day of SCT until death or last
follow-up. Progression of ATL was deﬁned as relapse after remission, devel-
opment of new lesions, or increase inmeasurable disease or in the number ofTransplantation.
Table 1
Patient and Transplantation Characteristics
Characteristics (n ¼ 56) Value
Age, median (range), yr 57 (37-69)
Age  60 37 (66.1%)
Sex
Male 28 (50.0%)
Female 28 (50.0%)
Disease subtype
Acute 28 (50.0%)
Lymphoma 26 (46.4%)
Chronic 1 (1.8%)
Smoldering 1 (1.8%)
WBC count at diagnosis, median
(range), per mL
10,900 (2500-331,000)
LDH level at diagnosis, median (range), IU/L 352 (144-1736)
sIL-2R level at diagnosis, median (range),
per mL
11,153 (998-116,100)
Months from diagnosis to SCT, median (range) 196 (60-3690)
 3 months 7 (12.5%)
3-6 months 17 (30.4%)
> 6 months 32 (57.1%)
Disease status at SCT
CR 23 (41.1%)
Non-CR 33 (58.9%)
PR 19 (33.9%)
REF 10 (17.9%)
REL 4 (7.1%)
LDH level at diagnosis, median (range), IU/L 218 (150-766)
sIL-2R level at SCT, median (range), U/mL 1219 (351-37,387)
HCT-CI score*
0 22 (41.5%)
1 11 (20.8%)
2 9 (17.0%)
3 6 (11.3%)
4-7 5 (9.4%)
Donor
MRD 20 (35.7%)
MUD 22 (39.3%)
MMD 14 (25.0%)
Sex disparity
Match 32 (57.1%)
Mismatch 24 (42.9%)
Male to female 15 (26.8%)
Female to male 9 (16.1%)
Stem cell source
BM 39 (69.6%)
PBSCy 11 (19.6%)
CB 6 (10.7%)
Conditioning regimen
MAC 17 (30.4%)
RIC 39 (69.6%)
TBI
Yes 40 (71.4%)
No 16 (28.6%)
GVHD prophylaxis
CSPþMTX 22 (39.3%)
TKþMTX 25 (44.6%)
CSP alone or TK alone 7 (12.5%)
WBC indicates white blood cell; LDH, lactate dehydrogenase; SCT, stem
cell transplantation; sIL-2R, soluble interleukin-2 receptor; CR, complete
remission; PR, partial remission; REF, primary refractory; REL, relapse; MRD,
HLA-matched related donor; MUD, HLA-matched unrelated donor; MMD,
HLA-mismatched donor; BM, bone marrow; PBSC, peripheral blood stem
cell; CB, cord blood; MAC, myeloablative conditioning; RIC, reduced-
intensity conditioning; LDH lactate dehydrogenase; HCT-CI, hematopoietic
cell transplant comorbidity index; TBI, Total body irradiation; GVHD, graft-
versus-host disease; CSP, cyclosporin A; MTX, methotrexate; TK, tacrolimus.
Data presented are n (%) unless otherwise indicated.
* HCT-CI score was not available in 3 patients.
y PBSC were from an MRD in all cases because donation of PBSC from
unrelated donors is not permitted in Japan until 2010.
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was deﬁned as survival without progression of ATL.
Endpoint and Statistical Analysis
The primary endpoint of this study was OS rate of the patients.
Descriptive statistical analysis was performed using the chi-square test or
Fisher’s exact test as appropriate for categorical variables and using the 2-
sided Wilcoxon rank-sum test for continuous variables. The probabilities
of OS and PFS were estimated using the Kaplan-Meier method. Disease
progression rates and TRM rates were estimated using cumulative incidence
analysis and considered as competing risks, and Gray’s test was used for
group comparison of cumulative incidence. The effects of various patient
and disease categorical variables on survival probabilities were examined
using the log-rank test, and the following variables were included in sub-
group analyses: age of the patients, sex of the patients, levels of serum
soluble interleukin-2 receptor (sIL-2R) at diagnosis and SCT, disease status at
SCT, disease subtypes, months from diagnosis to SCT, levels of lactate de-
hydrogenase (LDH) at diagnosis and at SCT, donor, stem cell source, intensity
of the conditioning regimen, GVHD prophylaxis, and CGVHD. All P values
were 2-sided and a P value of .05 was used as the cutoff for statistical sig-
niﬁcance. Multivariate analysis for OS was performed using the Cox pro-
portional hazards regression model.
RESULTS
Patients and Transplantation Characteristics
Patients and SCT characteristics are summarized in
Table 1. The median age of the patients was 57 years, and one
half of the patients were male. Twenty-eight (50.0%) patients
had acute type and 22 (46.4%) patients had lymphoma type.
HTLV-1 serostatus of donors were available in 47 patients,
and only 2 (4.3%) donors were positive for HTLV-1. After
induction chemotherapies that were mainly CHOP or VCAP-
AMP-VECP regimens [12], 23 (41.1%) patients received allo-
SCT in complete remission (CR) and 33 (58.9%) patients
received allo-SCT in non-CR. Nineteen patients had high level
of sIL-2R at SCT. Among the patients with high level of sIL-2R
at SCT, only 1 patient was in CR at SCT and the other 18 pa-
tients were not in CR at SCT. There was a correlation between
disease status at SCT and sIL-2R at SCT (median, 824 U/mL
[range, 351 to 2530] in CR patients versus a median of 2325
U/mL [range, 435 to 37,384 U/mL] in non-CR patients; P ¼
.02). Seventeen (30.4%) patients received myeloablative
conditioning, which consisted of high-dose cyclophospha-
mide and total body irradiation with or without VP-16, and
39 (69.6%) patients received reduced-intensity conditioning,
which consisted of ﬂudarabine with either busulfan or
melphalan low-dose total body irradiation of 2 to 4 Gray.
Transplantation Outcomes
Engraftment and GVHD
Except for 3 patients who died before engraftment, 53
(94.6%) patients achievedneutrophil engraftment at amedian
of 16 (range, 9 to 31) days. Platelet engraftment could be
assessed in 52 patients, and 40 (76.9%) patients achieved
platelet engraftment at amedian of 27 (range,14 to 415) days.
All patients who achieved neutrophil engraftment were
assessed for AGVHD. Overall AGVHD, grade II to IV AGVHD,
and grade III to IV AGVHD occurred in 40 (75.5%), 31 (58.5%),
and 8 (15.1%) of the evaluable patients, respectively. The
median onset of AGVHDwas 29 (range, 8 to 101) days. CGVHD
was assessed in 43 patients who survived beyond day 100
after SCT. CGVHD occurred in 24 (55.8%) of the evaluable pa-
tients at amedianonset dayof 168 (range, 69 to495) days, and
extensive CGVHD occurred in 16 patients (37.2%).
Disease progression and TRM
Cumulative incidences of disease progression and TRM
are shown in Figure 1. Fourteen (25.0%) patients showeddisease progression at a median of 74 (range, 12 to 273) days
after SCT. Twelve patients with disease progression after SCT
died of ATL. One of the other 2 patients with disease pro-
gression died of a transplantation-related complication in
Figure 1. Cumulative incidence analyses of disease progression and TRM after
SCT. Cumulative incidences of (a) TRM and (b) disease progression after allo-
SCT. Disease progression and TRM were considered as competing risks.
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time from disease progression to death was 92 (range, 32 to
399) days. Eighteen (32.1%) patients died of TRM at a median
of 148 (range, 12 to 2143) days. The causes of TRM included
infection (n¼ 6), AGVHD (n¼ 4), veno-occlusive disease (n¼
2), CGVHD (n ¼ 2), thrombotic microangiopathy (n ¼ 1),
cerebral infarction (n ¼ 1), chronic renal failure (n ¼ 1), and
suicide (n ¼ 1). Univariate analysis showed that a high level
of sIL-2R at SCT ( 2000 U/mL) was signiﬁcantly associated
with disease progression (P ¼ .02), whereas male sex tended
to be associated with increased risk (P ¼ .06). Non-CR at SCT
was marginally signiﬁcant for TRM (P ¼ .07).
Survival
The median follow-up period for survivors was 48 (range,
17 to 134) months. One-year OS and 5-year OS rates were
55.4% and 46.1%, respectively. One-year PFS and 5-year PFS
were51.1%and45.6%, respectively. The survival curve reached
aplateauat22months afterSCT (Figure2).Male sex (P¼ .002),
a high level of sIL-2R both at diagnosis ( 10,000 U/mL,O
S
Months after SCT
CR
non-CR
P = .03
PF
S
Months after SCT
CR
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P = .02
T in all patients. The solid line shows the overall survival curve and the dotted
ute type according to disease status at SCT. (C) Overall survival in patients with
tients with acute type according to disease status at SCT. (E) Progression-free
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CR at SCT (P < .001) were identiﬁed as signiﬁcant risk factors
for OS by univariate analyses. Disease subtypes and other
factors were not risk factors for OS. We tested several cutoff
points of sIL-2R for determining the most signiﬁcant cutoff
points for survival and found that the cutoff levels of 10,000 at
diagnosis and 2000 at SCT weremost signiﬁcantly associated
with survival.Worse survival formale patients andpatients in
non-CR at SCT were conﬁrmed by using multivariate analysis
(hazard ratio, 3.40 [95% conﬁdence interval (CI), 1.44 to 8.02]
for male patients; hazard ratio, 4.45 [95% CI, 1.82 to 10.87] for
non-CR patients). The levels of sIL-2R at SCT were not
included in multivariate analysis, which included disease
status, because the levelsof sIL-2Rat SCTwerecorrelatedwith
the disease status at SCT. Inpatients in non-CRat SCT, the level
of sIL-2R was signiﬁcantly associated with OS (P ¼ .02)
(Figure 3B), regardless of disease subtype (P ¼ .02 for acute
type and P¼ .01 for lymphoma type) (Figure 3C,D), and a high
level of sIL-2R at SCTwas determined to be a prognostic factor
when itwas used as an alternative variable todisease status at
SCT inmultivariate analysis (hazard ratio, 5.95 [95% CI, 2.14 to
17.9]). We performed multivariate analysis for non-CR pa-
tients using a level of sIL-2R at SCT and sex of the patients as
variables, and a high level of sIL-2R at SCT remained signiﬁ-
cant evenafter adjustmentbysexof thepatients (hazard ratio,
2.73 [95% CI, 1.07 to 7.90]). The other variables were not
conﬁrmed to be signiﬁcant by multivariate analysis.
DISCUSSION
A previous retrospective study on allo-SCT for ATL in
Japan [4] demonstrated 3-year OS of 36.0%, and a prospective
study on allo-SCT using a reduced-intensity conditioning
regimen showed 5-year OS of 34.0% [5]. The 5-year OS rate in
the present study was 46.1% and the survival curve reached a
plateau at 22 months after SCT. Although the results of the
present study are worse than the results we previously re-
ported [6], the difference in results is probably due to theMonths after Transplantation
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Figure 3. Overall survival according to level of serum sIL-2R at SCT. A high level of
Patients who were in non-CR at SCT. (C) Patients with acute type of ATL. (D) Patientselection bias of the patients or might simply reﬂect a multi-
institutional study versus a selected institutional study.
In previous nationwide studies on ATL in Japan, advanced
age, male sex, non-CR at SCT, poor performance status, SCT
from unrelated donors, or SCT using cord blood were associ-
ated with poor survival after allo-SCT [3,4]. Multivariate
analysis in this study conﬁrmed that male patients and pa-
tients in non-CR at SCTwere at risk for poorOS. Therewere no
differences in characteristics of the patients and SCT between
male and female patients (data not shown), and the incidence
of disease progression after allo-SCT was increased in male
patients with marginal signiﬁcance (P ¼ .06). There has been
no report showing worse survival in male patients after
chemotherapy for ATL. It is thus tempting to speculate that
this difference is due to the difference in allogeneic immune
responses betweenmale and female recipients after allo-SCT.
Although a high level of sIL-2R has been reported to
reﬂect disease progression of ATL [13,14], the clinical signif-
icance of sIL-2R for patients who received allo-SCT remains
to be determined. In this study, a high level of sIL-2R at SCT
was identiﬁed as a signiﬁcant risk factor for OS by univariate
analysis. We did not include sIL-2R at SCT in the multivariate
analysis because the level of sIL-2R at SCT was stringently
correlatedwith disease status at SCT. However, a high level of
sIL-2R at SCT was determined to be a prognostic factor when
it was used as an alternative variable to disease status at SCT
in multivariate analysis, and a high level of sIL-2R at SCT was
a risk factor for OS in patients with non-CR at SCT, regardless
of the sex of the patient. Only sIL-2R at SCT was identiﬁed as
a risk factor for disease progression. Thus, sIL-2R at SCT could
be a useful surrogate marker for disease status. Although
transplantation outcomes in non-CR patients were inferior to
those in CR patients, as has been previously reported [3,4],
the level of sIL-2R at SCT was signiﬁcantly associated with OS
in non-CR patients, indicating that sIL-2R level at SCT could
be used as a decision-making parameter for selection of allo-
SCT for patients in non-CR. Additional chemotherapies or aP = .01
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serum sIL-2R at SCT was deﬁned as 2000 U/mL or higher. (A) All patients. (B)
s with lymphoma type of ATL.
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tients who have high level of sIL-2R may improve the
outcome of allo-SCT, although this hypothesis needs to be
tested in a prospective study.
In conclusion, although the current study has several
limitations that should be considered when reviewing the
ﬁndings, including the use of a retrospective design and a
small number of patients, it showed encouraging results of
allo-SCT for patients with ATL in both CR and non-CR with
low levels of sIL-2R at SCT.
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